Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Completed · Phase 1

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir

Key facts

Study ID

NCT00873223

Run by

Novo Nordisk A/S

People needed

33

Starts

2009-03-01

Expected to finish

2009-09-01

Last updated by the study team

2017-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with type 2 diabetes
• BMI less than 45.0 kg/m2
• Insulin naive
• Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%

You may not qualify if…

• Any clinically significant disease other than type 2 diabetes
• Currently using daily insulin
• Thiazolidinione use or other injectable diabetes medications within the last 3 months

Where it is running

• Novo Nordisk Investigational Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.